GILEAD SCIENCES, INC.

CIK 0000882095 · FOSTER CITY, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-03 · Open the SEC source ↗

GILEAD SCIENCES, INC. reported 5 positions worth $1.65B as of June 30, 2026 (13F filed August 3, 2026). Largest holding: RCUS (58.8%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$1.65B

2026 Q2

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q2

Positions Changes Mix History BacktestPRO

5 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	RCUS	Arcus Biosciences Inc.	SH	$968.8M	58.76%	31,424,760	—	—
▸ 2	LKFT	Lakefront Biotherapeutics	SH	$500.2M	30.34%	16,707,477	—	—
▸ 3	ASMB	Assembly Biosciences Inc.	SH	$136.8M	8.29%	4,977,089	—	—
▸ 4	KYTX	Kyverna Therapeutics Inc.	SH	$36.8M	2.23%	4,126,119	—	—
▸ 5	98422T100	Xilio Therapeutics Inc.	SH	$6.2M	0.38%	650,389	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does GILEAD SCIENCES, INC. hold as of Q2 2026?

GILEAD SCIENCES, INC. reported 5 positions worth $1.65B in its Q2 2026 13F filing. Largest positions: RCUS (58.8%), LKFT (30.3%), ASMB (8.3%), KYTX (2.2%) and Xilio Therapeutics Inc. (0.4%).

What did GILEAD SCIENCES, INC. buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did GILEAD SCIENCES, INC. sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.